Public advisory - Certain bottles of JAMP Venlafaxine XR 37.5 mg capsules recalled due to mislabelling that could lead to overdose
OTTAWA, ON, June 21, 2023 /CNW/ -
Summary
Product: JAMP Venlafaxine XR 37.5 mg (lot PTC5140A) sold to pharmacies in bottles of 100 capsules for dispensing.
Issue: Health products ? Labelling
What to do: Check the capsules in your pharmacy bottle of JAMP Venlafaxine XR 37.5 mg capsules to make sure it contains 37.5 mg capsules (grey / pink in colour) and not 150 mg capsules (caramel in colour). If it contains 150 mg capsules, or if you are unsure, return it to your pharmacy as soon as possible. Your pharmacist will check it and provide a replacement with the correct capsules, if needed.
Contact your health care professional if you have taken the wrong dose of your medication. Seek medical attention immediately if you experience any serious side effects from Venlafaxine XR, which may include allergic reactions, gastrointestinal bleeding, seizures, heart rhythm problems, blurred vision, eye pain, or severe headache.
Affected products
Product
DIN
Lot
Expiry date
JAMP Venlafaxine XR 37.5 mg
02516535
PTC5140A
09/2024
Issue
JAMP Pharma Corporation is recalling mislabelled bottles from lot PTC5140A of Venlafaxine extended release (XR) capsules after one bottle labelled to contain 37.5 mg capsules was found to contain 150 mg capsules. Only the mislabelled bottles are being recalled.
Venlafaxine XR is a prescription drug used to relieve symptoms of major depressive disorder and anxiety caused by generalized anxiety disorder, social anxiety disorder and panic disorder.
If pharmacists did not recognize the error, they may have repackaged and dispensed pharmacy bottles labelled as containing 37.5 mg capsules, but instead contained 150 mg capsules. This error could lead to patients taking a higher dose than prescribed.
Venlafaxine XR 37.5 mg capsules have a grey cap and pink body, with "RVn" printed on the cap and "37.5" printed on the body.
Venlafaxine XR 150 mg capsules are caramel in colour with "RVn" printed on the cap and "150" printed on the body.
Accidently taking more than the prescribed dose can lead to serious side effects. Side effects requiring immediate medical attention include allergic reactions, gastrointestinal bleeding (signs include vomiting blood, passing blood in stool or black stool), seizures, heart rhythm problems, blurred vision, eye pain and severe headache. A sudden dose increase may also cause chills, high blood pressure, decreased appetite, nausea, agitation, dizziness, sleepiness, tremor, yawning or sweating.
The Department is monitoring the company's recall and will inform the public if any new health risks are identified.
What you should do
Check the capsules in your pharmacy bottle of JAMP Venlafaxine XR 37.5 mg capsules to make sure it contains 37.5 mg capsules (grey / pink in colour) and not 150 mg capsules (caramel in colour). If you are unsure, contact your pharmacist to check if your bottle contains the correct capsules.
If you see incorrect capsules, stop taking the medication and contact your pharmacy immediately for a replacement product. Return the affected product to your pharmacy for proper disposal.
Contact your health care professional if you have taken the wrong dose of your medication. Seek medical attention immediately if you experience any serious side effects from Venlafaxine XR, which may include allergic reactions, gastrointestinal bleeding, seizures, heart rhythm problems, blurred vision, eye pain, or severe headache.
Contact JAMP Pharma Corporation by email at [email protected] if you have questions about this recall.
Precision BioSciences, Inc. , an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today...
XORTX Therapeutics Inc. ("XORTX" or the "Company") , a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its press releases of March 11 and April 30,...
With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories...
NADclinic Group and Bontac Bio-Engineering (Shenzhen) Co., Ltd have officially entered into a dynamic strategic partnership to collaboratively focus on the future of global health and wellness. Synergistically leveraging their collective expertise...
Drug Farm announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of DF-003, a first-in-class, oral, potent, highly selective alpha-kinase 1 (ALPK1) inhibitor for clinical evaluation in...
'Companion Diagnostics: Technologies and Markets' is all about using special tests alongside certain medicines to figure out which treatment will work best for each person. These tests are called companion diagnostics because they go together with...